Swaranimakash Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 1.00 M
as on 16-11-2024
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.79 Cr
as on 16-11-2024
- Revenue 1140.40%
(FY 2023)
- Profit -12.36%
(FY 2023)
- Ebitda 354.32%
(FY 2023)
- Net Worth -117.51%
(FY 2023)
- Total Assets 1.54%
(FY 2023)
About Swaranimakash Life Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹4.79 Cr.
Swaran Singh and Akash Singh serve as directors at the Company.
- CIN/LLPIN
U74999UR2018PTC008988
- Company No.
008988
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Sep 2018
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Swaranimakash Life Sciences Private Limited offer?
Swaranimakash Life Sciences Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Third Party Manufacturing.
Who are the key members and board of directors at Swaranimakash Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swaran Singh  | Director | 04-Sep-2018 | Current |
| Akash Singh | Director | 04-Sep-2018 | Current |
Financial Performance of Swaranimakash Life Sciences.
Swaranimakash Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1140.4% increase. The company also saw a substantial fall in profitability, with a 12.36% decrease in profit. The company's net worth observed a substantial decline by a decrease of 117.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Swaranimakash Life Sciences?
Unlock access to Swaranimakash Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 30 Jan 2020 | ₹4.79 Cr | Open |
How Many Employees Work at Swaranimakash Life Sciences?
Unlock and access historical data on people associated with Swaranimakash Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Swaranimakash Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Swaranimakash Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
